Can nighttime scents affect walking, cognition and sleep in middle-aged adults?
| ISRCTN | ISRCTN98389755 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN98389755 |
| Sponsor | University of Haifa |
| Funder | Kimba AI |
- Submission date
- 14/11/2026
- Registration date
- 18/11/2026
- Last edited
- 18/11/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
During middle age, changes in sleep, thinking abilities, and walking performance may begin to emerge. Previous research suggests that exposure to different smells during sleep may influence brain function, but its effects on walking and cognitive performance in middle-aged adults remain unclear.
This study aimed to investigate whether nighttime exposure to pleasant smells could improve walking performance, cognitive function, and sleep quality in adults aged 45–60 years.
Who can participate?
Community-dwelling adults aged 45–60 years
What does the study involve?
Following a 1-week baseline period, participants completed two 3-week intervention periods in random order: one involving nighttime exposure to fragrances and the other involving an odorless control condition. There was no break between the two periods.
A programmable scent-diffusion device (Kimba Scent Device, model V4) was installed near each participant's bed. During the active intervention, three fragrances (lavender, bergamot, and sandalwood) were delivered in random order. Participants activated the device when going to bed. Diffusion began 40 minutes later and continued for about 3 hours and 45 minutes, using brief pulses that were more frequent at the beginning of the night. During the control period, the same device operated without releasing fragrances.
Participants underwent assessments of walking speed, walking while performing a mental arithmetic task, and cognitive abilities, including verbal fluency. These assessments were performed at baseline and after each intervention period.
Sleep was monitored using Garmin wrist-worn devices, daily sleep diaries, and questionnaires. Participants also completed morning attention tests.
What are the possible benefits and risks of participating?
The findings are intended to improve understanding of whether nighttime olfactory stimulation may offer a practical approach to supporting cognitive and physical functioning during middle age.
Where is the study run from?
University of Haifa (Israel)
When is the study starting and how long is it expected to run for?
March 2025 to December 2025
Who is funding the study?
The study was funded by Kimba AI, the company that developed the scent-diffusion device
Who is the main contact?
Khalil Iktilat, ikt.khalil@gmail.com
Contact information
Principal investigator
Faculty of Social Welfare and Health Sciences
University of Haifa
199 Abba Khoushy Avenue, Mount Carmel
P.O. Box 3338
Haifa
3103301
Israel
| Phone | +972 (0)549001609 |
|---|---|
| magmon@univ.haifa.ac.il |
Principal investigator, Scientific, Public
Dabburiya
Dabburiya
1691000
Israel
| Phone | +972 (0)507555710 |
|---|---|
| ikt.khalil@gmail.com |
Principal investigator
Faculty of Social Welfare and Health Sciences
University of Haifa
199 Abba Khoushy Avenue, Mount Carmel
P.O. Box 3338
Haifa
3103301
Israel
| Phone | +972 (0)546607480 |
|---|---|
| tshochat@univ.haifa.ac.il |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | Crossover |
| Purpose | Basic science |
| Scientific title | Nocturnal olfactory stimulation and dual-task gait in midlife: a randomized crossover |
| Study objectives | To investigate the effects of nocturnal olfactory stimulation on cognitive function, gait performance, and sleep quality in community-dwelling middle-aged adults aged 45–60 years, compared with an odorless control condition, using a randomized, single-blind crossover design. |
| Ethics approval(s) |
Approved 05/03/2025, Faculty Ethics Committee for Research Involving Human Participants, Faculty of Social Welfare and Health Sciences, University of Haifa (199 Abba Khoushy Avenue, Mount Carmel, Haifa, 3103301, Israel; +972 (0)4 8240257; Ethics-health@univ.haifa.ac.il), ref: 086/25 |
| Health condition(s) or problem(s) studied | Sleep quality, cognitive function, and gait performance |
| Intervention | Participants were randomly allocated using a lottery method to one of two intervention sequences: Sequence A: Three weeks of nocturnal olfactory stimulation followed by three weeks of odorless control. Sequence B: Three weeks of odorless control followed by three weeks of nocturnal olfactory stimulation. Both sequences were preceded by a one-week baseline period. There was no washout period between the two intervention periods. A 1-week baseline period preceded the intervention. Olfactory stimulation was delivered using the Kimba Scent Device (model V4, developed by Kimba AI), installed by a trained technician on a bedside table within 80 cm of the center of the participant's pillow. Three fragrances were used: lavender, bergamot, and sandalwood, selected from different fragrance families. The fragrances were delivered in random order without a fixed repeating sequence. Participants activated the device when getting into bed with the intention of sleeping. Odor diffusion began 40 minutes after activation and continued for 3 hours and 45 minutes each night. Each diffusion pulse lasted 40 seconds. Pulses were delivered every 7 minutes during the first 45 minutes and every 10 minutes during the subsequent 3 hours. During the odorless control condition, the same device operated according to an identical schedule without odor delivery. Both intervention periods lasted 21 nights. Outcomes were assessed at baseline and after each intervention period. Device activity was monitored through system logs to assess adherence to the intervention protocol. For the assessment timepoints, baseline (week 0) refers to the assessment immediately after the one-week baseline monitoring period and before the first intervention period. Week 3 and week 6 refer to the end of the first and second intervention periods, respectively. Daily and nightly recordings are summarised separately for the corresponding study phase. |
| Intervention type | Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Kimba Scent Device, Model V4 |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 05/12/2025 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 45 Years |
| Upper age limit | 60 Years |
| Sex | All |
| Target sample size at registration | 54 |
| Total final enrolment | 54 |
| Key inclusion criteria | 1. Adults aged 45–60 years 2. Community-dwelling individuals 3. Independent in activities of daily living (ADL) 4. Native or near-native Hebrew proficiency 5. Regular use of an iPhone compatible with the study application 6. Willingness to participate and provide written informed consent |
| Key exclusion criteria | 1. Sleep apnea, insomnia, or other severe sleep disorders, based on self-report during initial telephone screening 2. Self-reported sensitivity to odors 3. Self-reported olfactory impairment 4. Neurological diseases or acute medical conditions, including orthopedic conditions |
| Date of first enrolment | 05/03/2025 |
| Date of final enrolment | 10/07/2025 |
Locations
Countries of recruitment
- Israel
Study participating centres
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
16/11/2026: Study's existence confirmed by the Faculty Ethics Committee for Research Involving Human Participants, Faculty of Social Welfare and Health Sciences, University of Haifa, Israel.